SPONSOR
Otsuka Pharmaceutical Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2, Phase 3
Clinical Trials by Otsuka Pharmaceutical Co., Ltd.
NCT06875986
Recruiting
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Alzheimer Disease
NCT07225712 Phase 3
Recruiting
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Schizophrenia
NCT07086313 Phase 2, Phase 3
Recruiting
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Attention-Deficit Hyperactivity Disorder(ADHD)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology